NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
37 hedge funds and large institutions have $92.6M invested in NKGen Biotech, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.2M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$11M |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$5.85M |
| 4 |
6CM
683 Capital Management
New York
|
+$4.88M |
| 5 |
FTCM
Fir Tree Capital Management
New York
|
+$4.88M |
Top Sellers
NKGN Hedge Fund Activity: Q3 2021 in Review
37 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2021, worth a combined $92.6M.
Buyers outnumbered sellers: 37 funds opened new NKGN positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $13.2M.
- 37 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $92.6M of NKGen Biotech, Inc. Common Stock stock for Q3 2021.
- 37 funds opened new NKGen Biotech, Inc. Common Stock positions in Q3 2021 and 0 closed out, a net change of +37 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2021 was Adage Capital Partners, an estimated $13.2M added.
Based on aggregated 13F filings for Q3 2021.